Severe neutropenia associated with oral terbinafine therapy.
Gupta
A K
AK
Department of Medicine, Sunnybrook Health Science Center and the University of Toronto, Ontario, Canada.
Soori
G S
GS
Del Rosso
J Q
JQ
Bartos
P B
PB
Shear
N H
NH
D000284:Administration, Oral; D000935:Antifungal Agents / Q000009:adverse effects*; D016470:Bacteremia / Q000382:microbiology; D005533:Foot Dermatoses / Q000188:drug therapy / Q000382:microbiology; D005891:Gingivitis / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects*; D009503:Neutropenia / Q000139:chemically induced*; D014009:Onychomycosis / Q000188:drug therapy; D011552:Pseudomonas Infections; D011550:Pseudomonas aeruginosa; D013203:Staphylococcal Infections; D013280:Stomatitis / Q000139:chemically induced; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine